NCT04551677View on ClinicalTrials.gov

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

December 18, 2020

Study Completion Date

December 18, 2020

Conditions
Influenza ImmunizationHealthy Volunteers
Interventions
BIOLOGICAL

Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation

"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)"

BIOLOGICAL

Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation

"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: IM"

Trial Locations (2)

40004

Investigational Site Number 8400001, Bardstown

84121

Investigational Site Number 8400002, Salt Lake City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04551677 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively | Biotech Hunter | Biotech Hunter